Drug ID:Drug133
Drug Name:GSK2586184
CID:44603362
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT02000453
Molecular Formula:C22H23N5O2
Molecular Weight:389.4 g/mol
Isomeric SMILES:CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C
Synonyms:Solcitinib; 1206163-45-2; GLPG-0778; GLPG0778; GSK2586184A; GSK2586184; GSK 2586184; GSK-2586184; N-(5-(4-(3,3-Dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide; N-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1066 44603362 Solcitinib 3716 JAK1 Homo sapiens (human) Inhibitor
dt1067 44603362 Solcitinib 3716 JAK1 Homo sapiens (human) 25724932 Tyrosine-protein kinase JAK1 inhibitor
dt1068 44603362 Solcitinib 3716 JAK1 Homo sapiens (human) Inhibition
dt1069 44603362 Solcitinib 3717 JAK2 Homo sapiens (human) Inhibition
dt1070 44603362 Solcitinib 3718 JAK3 Homo sapiens (human) Inhibition
dt1071 44603362 Solcitinib 3716 JAK1 Homo sapiens (human) Modulator
dt1072 44603362 Solcitinib 2049 EPHB3 Homo sapiens (human) Inhibitor
dt1073 44603362 Solcitinib 2047 EPHB1 Homo sapiens (human) Inhibitor
dt1074 44603362 Solcitinib 2048 EPHB2 Homo sapiens (human) Inhibitor
dt1075 44603362 Solcitinib 7297 TYK2 Homo sapiens (human) Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT02000453 Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis. PHASE1 TERMINATED GlaxoSmithKline Colitis, Ulcerative DRUG: GSK2586184 400mg Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05633706 Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis NULL RECRUITING Nimble Science Ltd. Irritable Bowel Syndrome|Crohn Disease|Celiac Dis… DEVICE: fluid biopsy capsule Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05602116 ASC - Autism Study PHASE1 COMPLETED Cell to Cure ApS Autism Spectrum Disorder|Gastrointestinal Dysfunc… DRUG: Adipose tissue derived mesenchymal stromal/… Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05573685 Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training NA COMPLETED Click Therapeutics, Inc. Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… DEVICE: DiNaMo Study App|DEVICE: Placebo App Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PHASE2 ACTIVE_NOT_RECRUITING Palatin Technologies, Inc Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… DRUG: PL8177 Placebo|DRUG: PL8177 Details
NCT05451433 The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS NA UNKNOWN Fakultas Kedokteran Universitas Indonesia Irritable Bowel Syndrome DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placebo Details
NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Innovent Biologics (Suzhou) Co. Ltd. Ulcerative Colitis (UC) DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… Details
NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis PHASE2 TERMINATED Vedanta Biosciences, Inc. Ulcerative Colitis|Colitis, Ulcerative BIOLOGICAL: VE202|DRUG: Vancomycin Oral Capsule|O… Details
NCT07145580 Combined Lactulose H2-breath Test With Abdominal Imaging NULL RECRUITING Klinik Arlesheim Food Intolerance Syndromes|Small Intestinal Bacte… None Details
NCT05291689 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC PHASE2 COMPLETED Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Inflammatory Bowel Diseases|Colitis, Ulcerative DRUG: MORF-057 Details
NCT05271838 Protein and Magnesium in Ulcerative Colitis NA UNKNOWN University of Aarhus Inflammatory Bowel Diseases|Colitis, Ulcerative|M… DIETARY_SUPPLEMENT: Magnesium acetate mixture (30… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis

PMID: 28790099
Year: 2017
Relationship Type: Treatment Score: 6.3

Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerat…

View Details